HilleVax (NASDAQ:HLVX) Shares Down 5.3%

HilleVax, Inc. (NASDAQ:HLVX)’s stock price fell 5.3% on Tuesday . The company traded as low as $13.09 and last traded at $13.17. 23,761 shares were traded during trading, a decline of 81% from the average session volume of 122,535 shares. The stock had previously closed at $13.91.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of HilleVax in a research report on Thursday, March 21st.

HilleVax Trading Down 6.3 %

The firm’s 50-day simple moving average is $16.24 and its 200 day simple moving average is $14.65. The company has a current ratio of 10.62, a quick ratio of 10.62 and a debt-to-equity ratio of 0.10. The stock has a market cap of $648.09 million, a P/E ratio of -4.44 and a beta of 0.65.

HilleVax (NASDAQ:HLVX) last posted its quarterly earnings data on Wednesday, March 20th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.02. As a group, equities research analysts anticipate that HilleVax, Inc. will post -3.22 earnings per share for the current year.

Insider Activity at HilleVax

In other HilleVax news, Director Aditya Kohli sold 8,866 shares of HilleVax stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $132,369.38. Following the completion of the sale, the director now owns 812,878 shares of the company’s stock, valued at approximately $12,136,268.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, Director Aditya Kohli sold 8,866 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $132,369.38. Following the transaction, the director now owns 812,878 shares in the company, valued at approximately $12,136,268.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Shane Maltbie sold 3,576 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $14.93, for a total transaction of $53,389.68. Following the transaction, the chief financial officer now owns 40,656 shares in the company, valued at approximately $606,994.08. The disclosure for this sale can be found here. In the last 90 days, insiders sold 78,039 shares of company stock worth $986,464,242. 29.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. grew its position in HilleVax by 80.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,753 shares of the company’s stock worth $30,000 after purchasing an additional 781 shares during the last quarter. Rhumbline Advisers grew its position in HilleVax by 3.2% in the 3rd quarter. Rhumbline Advisers now owns 27,414 shares of the company’s stock worth $369,000 after purchasing an additional 838 shares during the last quarter. Federated Hermes Inc. grew its position in HilleVax by 80.6% in the 3rd quarter. Federated Hermes Inc. now owns 2,113 shares of the company’s stock worth $28,000 after purchasing an additional 943 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in shares of HilleVax by 57.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,587 shares of the company’s stock valued at $43,000 after acquiring an additional 943 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in shares of HilleVax by 28.9% during the 2nd quarter. Royal Bank of Canada now owns 4,779 shares of the company’s stock valued at $82,000 after acquiring an additional 1,072 shares in the last quarter. Institutional investors own 86.42% of the company’s stock.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.